Novartis (NVS) saw its IBD SmartSelect Composite Rating jump to 96 Wednesday, up from 93 the day before. The new score indicates that shares of the company, which is No. 1 in its industry group, are now outperforming 96% of all stocks in terms of the most important fundamental and technical stock-picking criteria.
↑ X NOW PLAYING Find Top Growth Stocks With The IBD Screen Of The DayWinning stocks often have a 95 or higher grade in the early stages of a new price run, so that's a good starting point when looking for the best stocks to buy and watch.
Novartis stock is currently forming a cup with handle base, with a 112.98 buy point. Look for the stock to break out in volume at least 40% above average. Wednesday the drugmaker
Discover The 3 Keys To Successful Stock Investing
The stock also sports an 89 EPS Rating, which means its recent quarterly and longer-term annual earnings growth is outpacing 89% of all stocks. Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors, such as mutual funds and pension funds, over the last 13 weeks.
The Swiss company posted a 29% increase in earnings for Q4, to $1.29 per share. That marks two straight reports with rising EPS growth. Sales increased 15% year over year to $13.6 billion, up from 9% growth the prior quarter. Novartis is expected to report first quarter results on or around April 29.
Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use
Novartis earns the No. 1 rank among its peers in the 33-stock Medical-Ethical Drugs industry group. Phibro Animal Health (PAHC) and Jazz Pharmaceuticals (JAZZ) are also among the group's highest-rated stocks.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
Please follow James DeTar on Twitter @JimDeTar
YOU MAY ALSO LIKE:
Which Companies Are Now Outperforming 95% Of All Stocks?
View The Top-Rated Growth Stocks To Buy And Watch Right Now
See Which Stocks Just Came On — And Off — IBD's Top Stock Lists
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
Identify Bases And Buy Points With Pattern Recognition From MarketSmith
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。